Zurich Consensus: German Expert Opinion on the St. Gallen Votes on 15 March 2009 (11th International Conference at St. Gallen: Primary Therapy of Early Breast Cancer).
A German working group of 23 breast cancer experts discussed the results from the vote at this year's St. Gallen Consensus Conference on Primary Therapy for Early Breast Cancer (March 11-14, 2009) and came up with some concrete recommendations for day-to-day therapeutic decisions in Germany. Due the fact that the concept of the St. Gallen Consensus Conference merely allows for a minimal consensus, the objective of the working group was to provide practice-related recommendations for day-to-day clinical decisions in Germany. One area of emphasis at St. Gallen was tumor biology as a starting point for reaching individual therapeutic decisions. Intensive discussion was necessary with respect to the clinical relevance of predictive and prognostic factors. A new addition to the area of systemic therapy was a first-ever discussion of the adjuvant administration of bisphosponates and the fact that therapy with trastuzumab in HER2 overexpressing breast cancer has been defined as the standard for neoadjuvant therapy. The value of taxanes as a component of (neo)adjuvant chemotherapy as well as the value of aromatase inhibitors for the endocrine adjuvant treatment of postmenopausal patients were affirmed.
Erlangen University Women's Hospital, Berlin, Germany.
Matthias W
MW
Beckmann
Jens-Uwe
JU
Blohmer
Serban-Dan
SD
Costa
Klaus
K
Diedrich
Ingo
I
Diel
Wolfgang
W
Eiermann
Klaus
K
Friese
Bernd
B
Gerber
Nadia
N
Harbeck
Joern
J
Hilfrich
Wolfgang
W
Janni
Fritz
F
Jaenicke
Walter
W
Jonat
Manfred
M
Kaufmann
Marion
M
Kiechle
Uwe
U
Koehler
Rolf
R
Kreienberg
Gunter
G
von Minckwitz
Volker
V
Moebus
Ulrike
U
Nitz
Andreas
A
Schneeweiss
Christoph
C
Thomssen
Diethelm
D
Wallwiener